Clinical Trial Update: A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pharmacokinetics, efficacy and safety of subcutaneous CT-P44 vs Darzalex Faspro in combination with lenalidomide and dexamethasone in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CT-P44 (daratumumab biosimilar)
• DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT))
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Celltrion | Conditions: Refractory or Relapsed Multiple Myeloma | Phase 3 | Status: RECRUITING